Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05629793
Other study ID # DICOPERIA
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 14, 2022
Est. completion date November 2023

Study information

Verified date November 2022
Source Fundacin Biomedica Galicia Sur
Contact Alejandro García Caballero, MD
Phone 988 38 55 00
Email alejandro.alberto.garcia.caballero@sergas.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of persistent, diffuse and heterogeneous symptoms referred to as persistent COVID. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction, among others, and result in an impact on daily functioning. Symptoms may be new onset, appear after initial recovery from an acute episode of COVID-19, or persist after the initial illness. Cardiac variability (HRV) was initially used in COVID-19 to predict mortality in the acute setting. Dysautonomia which partly evaluates HRV is frequent in patients with persistent COVID. Several groups have used voice or other respiratory noise analysis for the diagnosis of acute COVID. Patients in the persistent COVID cohort will be able to be differentiated from an age, sex and vaccination status matched cohort of recovered COVID patients without sequelae by means of a model created by Machine Learning that will be trained using cardiac variability (HRV), skin conductance and acoustic analysis data. The primary objetive will be to obtain a classification algorithm by Machine Learning to differentiate the group of patients with persistent COVID diagnosis from the paired group of recovered COVID patients without sequelae.


Description:

This is a validation study of a Machine Learning algorithm for the diagnosis of persistent COVID using clinical diagnosis as the "gold standard". The sample will be composed of post-COVID patients, one group of which developed persistent COVID and another paired with the previous one with cured COVID without sequelae.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 136
Est. completion date November 2023
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Persistent COVID group: Inclusion Criteria: - Age =18 and =70 years of age - Confirmed infection (PCR) with SARS- CoV-2 until 03/28/2022 and thereafter date. - Symptoms include: fatigue, respiratory distress or cognitive dysfunction, among others. - Symptoms persist or appear more than 3 months after onset of infection. - Symptoms last longer than 2 months and are not better explained by another diagnosis. - Symptoms appeared after initial recovery or persisted since disease debut. - Symptoms may fluctuate or remit over time. - Patients have capacity to consent and agree to participate in the study. Exclusion Criteria: - Active COVID-19 infection. - Cardiac arrhythmia, pacemaker carrier. - Other pathologies with dysautonomia. - Raynaud's phenomenon. - Other diseases that may affect exercise capacity or be aggravated by exercise shall also be excluded, such as: Uncontrolled heart failure, severe or symptomatic aortic stenosis, pulmonary edema, acute respiratory failure, recent pulmonary thromboembolism, lower limb thrombosis, infections, thyrotoxicosis, or orthopedic inability to walk. Recovery COVID group Inclusion Criteria: - Age =18 and =70 years of age - Confirmed infection (PCR) with SARS- CoV-2 until 03/28/2022 and thereafter date. - Full functional recovery. - Follow-up by Primary Care. - They have not presented three months after the onset of the disease: fatigue, respiratory distress or cognitive dysfunction, among others. - Patients have capacity to consent and agree to participate in the study. Exclusion Criteria: - Active COVID-19 infection. - Cardiac arrhythmia, pacemaker carrier. - Other pathologies with dysautonomia. - Raynaud's phenomenon. - Other diseases that may affect exercise capacity or be aggravated by exercise such as: uncontrolled heart failure, severe or symptomatic aortic stenosis, pulmonary edema, acute respiratory failure, recent pulmonary thromboembolism, lower limb thrombosis, infections, thyrotoxicosis, or orthopedic inability to walk shall also be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Experimental tests
Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.

Locations

Country Name City State
Spain Complexo Hospitalario Universitario de Ourense Ourense
Spain Health Center A Cuña Ourense
Spain Health Center Novoa Santos Ourense
Spain Health Center Valle Inclán Ourense
Spain S.S. Computer Engineering (University of Vigo) Ourense
Spain Galicia Sur Health Research Institute (IISGS) - Hospital Álvaro Cunqueiro Vigo
Spain School of Telecommunication Engineering (University of Vigo) Vigo

Sponsors (3)

Lead Sponsor Collaborator
Fundacin Biomedica Galicia Sur Galician South Health Research Institute, University of Vigo

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Age Years 8 weeks
Other Sex Male, Female 8 weeks
Other Current treatment Treatment taken by the patient at the time of the study. 8 weeks
Other Date of PCR + SARS-CoV-2 DD-MMM-YYYY 8 weeks
Other Epidemic wave Of the 7 waves of COVID-19 that have occurred in Spain, a description will be given of the wave to which the infection of each patient included belonged. First, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth wave. 8 weeks
Other Vaccination status at the time of infection Number of vaccines doses at the time of infection 8 weeks
Other FVC Is the maximum volume of air exhaled, with the maximum possible effort, starting from a maximum inspiration in ml. 8 weeks
Other FEV1 The volume of air expelled during the first second of forced expiration in ml. 8 weeks
Other FEV1/ FVC Expressed as a percentage (%), it indicates the proportion of the FVC that is expelled during the first second of the forced expiratory maneuver. 8 weeks
Other CO diffusion test To evaluate the transfer of oxygen from the alveolar space to the hemoglobin of the erythrocytes contained in the pulmonary capillaries. Effective alveolar-capillary area available for gas transfer in the lung. (%) 8 weeks
Primary Differences of the group of patients with a persistent diagnosis of COVID from the age-matched group, sex and vaccination status of patients recovered from COVID without sequelae. Through an algorithm model created by Machine Learning that will be trained using cardic variability (HRV), skin conductance and acoustic analysis data. 8 weeks
Secondary Cardiac variability Number of times a contraction of the heart occurs in one minute, expressed in beats per minute, by means of a Polar chest strap, model H10. A baseline recording of 5 minutes duration will be taken, with the patient in a seated position. At the end of each test, recording is continued for 2 minutes to demonstrate the speed and degree of recovery after stress. 8 weeks
Secondary Voice recording Sounds produced by the patient at rest and after having performed the stress tests. The patient will be asked to take a deep breath and then pronounce the vowel /a/ in a sustained manner, in a comfortable tone and volume (3 times). 8 weeks
Secondary Skin conductance micro Siemens [µS]. By means of the Bitalino electrodermal activity recording system. It will be recorded at rest, during the Cold Pressor test and once it is finished, for at least two minutes, to assess the normalization of the conductivity curve. 8 weeks
Secondary 6MWT metres/min. The patient will walk the maximum distance they can in 6 minutes. 8 weeks
Secondary 1minSTST Number of repetitions performed after sitting down and getting up from a chair without supporting the hands as many times as possible for 1 minute.. 8 weeks
Secondary Cold Pressor test One hand is inserted into a container with water at 4-5ºC for 1 minute. Before and after the test, HRV, BP, and thermal conductance are recorded for 5 and 2 minutes -respectively- while lying supine. 8 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure